RMD Open
is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases
Impact Factor: 5.806
Citescore: 7.1
All metrics >>
Latest Articles
Psoriatic arthritis:
Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry25 May 2023
Sjo[x0308]gren syndrome:
Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögrens syndrome25 May 2023
Osteoarthritis:
Associations between markers of inflammation and altered pain perception mechanisms in people with knee osteoarthritis: a systematic review24 May 2023
Rheumatoid arthritis:
Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment23 May 2023
Video Abstract
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.
Find out moreEULAR Congress 2023
The 2023 EULAR Congress will be taking place on 31 May – 03 June in Milan, Italy as a hybrid event.
The aim of the European Congress of Rheumatology is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of people with rheumatic diseases.
View the Scientific Programme to plan your visit.
Most Read Articles
Rheumatoid arthritis:
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors2 November 2022
Lupus:
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial26 October 2022
Systemic sclerosis:
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort3 November 2022
Inflammatory arthritis:
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis8 February 2023
COVID-19 Content
Treatments:
Self-evidence-based digital care programme improves health-related quality of life in adults with a variety of autoimmune diseases and long COVID: a retrospective study16 May 2023
Infections:
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases17 April 2023